Bismuth subsalicylate in the prevention of colonization of infant mice with Campylobacter jejuni.
Infant mice were used for the evaluation of the efficacy of bismuth subsalicylate (BSS) in the prevention of the growth of Campylobacter jejuni in the intestine. The MIC90 of ten C. jejuni strains was 900 micrograms/ml. Of three dosage regimens tested, continuous treatment before and after the bacterial challenge, mimicking the way BSS is used in the prevention of traveller's diarrhoea, was the most effective. Growth inhibition was dose dependent; the high dose of 2000 micrograms per day was more effective than 300 micrograms per day. After cessation of treatment, campylobacter counts increased to the same level as in the control animals.
Hänninen
M L
ML
College of Veterinary Medicine, Department of Food and Environmental Hygiene, Helsinki, Finland.
D000818:Animals; D000831:Animals, Newborn; D001729:Bismuth / Q000494:pharmacology / Q000627:therapeutic use*; D002169:Campylobacter Infections / Q000517:prevention & control*; D002168:Campylobacter fetus / Q000187:drug effects* / Q000254:growth & development; D015169:Colony Count, Microbial; D003967:Diarrhea / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007422:Intestines / Q000382:microbiology; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D012459:Salicylates / Q000494:pharmacology / Q000627:therapeutic use*
D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D001729:Bismuth